All In Biotech

Drug Trial Radar · NCT03555149

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

96

Actual

Start

Sep 27, 2018

Primary completion

Sep 26, 2022

Study completion Sep 26, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.

Conditions

  • Colorectal Cancer

Interventions

  • RegorafenibDrug

    Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.

  • AtezolizumabDrug

    Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

  • Imprime PGGDrug

    Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.

  • BevacizumabDrug

    Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.

  • IsatuximabDrug

    Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.

  • SelicrelumabDrug

    Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.

  • IdasanutlinDrug

    Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.

  • AB928Drug

    AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.

  • LOAd703Genetic

    LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: From randomization until disease progression or loss of clinical benefit (up to 4 years)

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Yale University

    New Haven, Connecticut

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Peter MacCallum Cancer Center

    North Melbourne, Victoria, Australia

  • Centre Georges François Leclerc; Pharmacie des Essais Cliniques

    Dijon, France

  • Centre Leon Berard

    Lyon, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Asan Medical Center.

    Seoul, South Korea

  • CHUV; Departement d'Oncologie

    Lausanne, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.